A combination of diabetes treatments Januvia (Sitagliptin) and Forxiga (Dapagliflozin) is gaining popularity among domestic pharmaceutical companies. Although it can only be released after September next year due to patent rights issues, many domestic pharmaceutical companies are developing products. According to the pharmaceutical industry on the 6th, Chong Kun Dang recently applied for permission from the MFDS for a combination of Sitagliptin+Dapagliflozin.

Combination of Sitagliptin+Dapagliflozin succeeded in commercialization for the first time in Korea on the 21st of last month when Dapacombi of Daewon Pharmaceutical obtained permission. Two days later, Dongkoo Bio's Sitaflozin, the same ingredient